Dexcom’s FDA warning letter reveals unauthorized changes to sensors

A warning letter posted Tuesday by the Food and Drug Administration revealed quality control issues with Dexcom’s continuous glucose monitors. The FDA raised concerns with a design change to a component used in the resistance layer of Dexcom’s sensors.